UMN Pharma Inc. announced consolidated earnings results for the six months ended June 30, 2015. For the period, the company's net sales were ¥45 million compared with ¥1,078 million a year ago. Operating loss was ¥2,157 million compared with ¥1,796 million a year ago. Ordinary loss was ¥2,186 million compared with ¥1,967 million a year ago. Net loss was ¥2,183 million or ¥228.17 per basic share compared with ¥1,677 million or ¥198.63 per basic share a year ago. Loss before income taxes and minority interests was ¥2,186.7 million compared with ¥1,720.5 million a year ago. Net cash used in operating activities was ¥1,700.3 million compared with net cash provided by operating activities of ¥2,280.6 million a year ago. This was mainly due to loss before income taxes of ¥2,186,674,000, depreciation of ¥762,709,000, increase in inventories of ¥820,738,000 and increase in notes and accounts payable-trade of ¥891,310,000. Purchase of property, plant and equipment was ¥14.7 million compared with ¥2.2 million a year ago. Purchase of intangible assets was ¥0.22 million compared with ¥3.1 million a year ago.

For the year ending December 31, 2015, the company forecasts net sales of ¥2,254 million, operating loss of ¥1,697 million, ordinary loss of ¥1,844 million, net loss of ¥1,852 million or ¥193.54 per share compared to previous guidance of net sales of ¥5,224 million, operating loss of ¥878 million, ordinary loss of ¥1,025 million, net loss of ¥1,033 million or ¥108.14 per share.